English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Experimental studies suggest that visceral adiposity and adipose tissue dysfunction play a central role in obesity-related cardiometabolic complications. Impaired angiogenesis in fat has been implicated in the development of adipose tissue hypoxia, capillary rarefaction, inflammation, and metabolic dysregulation, but pathophysiological mechanisms remain unknown. In this study, we examined the role of a novel antiangiogenic isoform of vascular endothelial growth factor-A (VEGF-A), VEGF-A165b, in human obesity.

circulation

Antiangiogenic Actions of Vascular Endothelial Growth Factor-A <sub>165</sub> b, an Inhibitory Isoform of Vascular Endothelial Growth Factor-A, in Human Obesity

Antiangiogenic Actions of Vascular Endothelial Growth Factor-A 165 b, an Inhibitory Isoform of Vascular Endothelial Growth Factor-A, in Human Obesity

Antiangiogenic Actions of Vascular Endothelial Growth Factor-A ₁₆₅ b, an Inhibitory Isoform of Vascular Endothelial Growth Factor-A, in Human Obesity